My Health eNews

E-Home

Resource Center

E-Health Services

Daily Health News

Health Information

My Health eNews

VIEW ALL >

Username:

Password:

Remember me on this computer.


	FDA Approvals	Return to Daily Health Main Page.

	Generic Versions of Blood-Thinning Plavix Approved

	Drug helps prevent deadly clots
	THURSDAY, May 17 (HealthDay News) -- The first generic versions of the blood-thinning drug Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration. Brand-name Plavix, made by Brisol-Myers Squibb and Sanofi, was first FDA approved in 1997 to help prevent blood clots that could cause heart attack or stroke. It has been sanctioned for people who have had a recent heart attack or stroke, or who have at least a partial artery blockage, the agency said in a news release. The drug has a boxed label warning that it may not be effective for people who have certain genetic traits, or for those who take proton pump inhibiting drugs that are commonly prescribed to prevent gastroesophageal reflux disease. Gate Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceuticals received approval for 300 milligram clopidogrel. Apotex Corp., Aurobindo Pharma, Mylan Pharmaceuticals, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals, and Torrent Pharmaceuticals received approval for 75 milligram clopidogrel. Generic drugs must meet the same high quality standards as their brand-name counterparts and must be chemically equivalent, the agency said. More information To learn more about this drug, visit Medline Plus.


More FDA Approvals

	• Elelyso Approved for Gaucher Disease
	People with rare disorder lack enzyme

	• Afinitor Approval Expanded to Include Benign Kidney Tumors
	Growths caused by rare genetic disease

	• Votrient Approved to Treat Cancer That Begins in Soft Tissue
	Drug inhibits process that fuels tumor growth

	• Levaquin Approved to Treat or Prevent Plague
	Deadly disease rare in the United States

Health Content Provided By:

The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.